Human Milk Oligosaccharides (HMO) Market Size & Growth Forecast 2026–2035, By Segments (Application, Type), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growoth Outlook
Human Milk Oligosaccharides Market size was over USD 332.8 Million in 2025 and is likely to grow at a 13.8% CAGR between 2026 and 2035, attaining USD 1.21 Billion by 2035. The industry revenue for 2026 is calculated at USD 373.85 million.
Get more details on this report
Request Free Sample ReportHuman Milk Oligosaccharides (HMO) Market Intelligence Snapshot
Regional Market Dynamics
- North America leads due to a well-established infant nutrition industry, strong commercialization capabilities, mature regulatory frameworks, and early integration of advanced functional ingredients into premium formula products.
- Asia Pacific growth is driven by rising uptake of fortified infant nutrition, expanding distribution networks, and strong consumer demand for human-milk-like formulations, supporting a 15.46% CAGR.
Segment Momentum
- Infant Formula held an 86.17% market share in 2025 because it is the most established commercial application for HMOs, with manufacturers prioritizing formulations aligned with early-life nutrition and established purchasing patterns.
- Dietary Supplements are growing fastest as HMOs expand into wellness-focused products, supported by increasing interest in gut health, microbiome-support ingredients, and broader opportunities for product innovation beyond infant nutrition.
Market Expansion Drivers
- Growing consumer awareness of gut health boosting HMO supplement demand.
- Expanding infant formula applications supporting HMO integration for immunity and development.
- Increasing clinical nutrition investments driving advanced prebiotic ingredient commercialization.
Leading Market Participants
Global Market Forecast Snapshot
Market Outlook
Prominent companies in the human milk oligosaccharides market include DSM-Firmenich AG (Switzerland), BASF SE (Germany), Chr. Hansen Holding A/S (Denmark), FrieslandCampina Ingredients (Netherlands), Glycom A/S (Denmark), Inbiose NV (Belgium), Kyowa Hakko Bio Co., Ltd. (Japan), zuChem, Inc. (United States), Biosynth AG (Switzerland), Dextra Laboratories Limited (United Kingdom).Regional and Segment Outlook
North AmericaMarket Growth Drivers and Industry Trends
Rising attention to the link between the microbiome, digestion, and immune resilience is shifting supplement purchasing toward ingredients with clearer biological relevance, and that is strengthening demand in the human milk oligosaccharides (HMO) market. As consumers become more selective about prebiotic claims, HMOs are gaining traction because they are positioned as more targeted microbiome-support ingredients than conventional fibers, encouraging formulators to introduce capsules, powders, and functional nutrition products built around differentiated gut health benefits. This behavior is influencing market adoption by moving HMOs beyond infant-focused use cases and into broader wellness portfolios, where premium positioning and science-backed branding support higher-value commercialization.
Expanding infant formula applications supporting HMO integration for immunity and development
Infant nutrition remains the most commercially important pathway for ingredient uptake, and broader use of HMOs in formula is reinforcing demand in the human milk oligosaccharides (HMO) market by aligning product development more closely with the functional profile of human milk. Formula manufacturers are under pressure to narrow the perceived gap between breast milk and manufactured nutrition, which is making HMO inclusion a practical formulation decision tied to immunity support, digestive comfort, and early-life development claims. As a result, HMOs are moving from niche enhancement ingredients toward more strategic components in premium and specialized formula lines, aiding market expansion through deeper supplier partnerships, regulatory investment, and formulation scale-up.
Increasing clinical nutrition investments driving advanced prebiotic ingredient commercialization
Higher investment in clinical nutrition is accelerating the translation of microbiome science into commercially viable ingredients, creating favorable conditions for the human milk oligosaccharides (HMO) market. Companies active in medical nutrition, pediatric care, and condition-specific nutritional products are seeking prebiotics with stronger mechanistic backing and better compatibility with evidence-driven positioning, which makes HMOs increasingly attractive for product pipelines aimed at vulnerable or clinically managed populations. This is shaping the market through greater spending on process optimization, regulatory documentation, and targeted formulation development, all of which help move HMOs from research-intensive ingredients into broader commercial use.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Growing consumer awareness of gut health boosting HMO supplement demand | 2.00% | Moderate | Europe, North America | High | Near Term |
| Expanding infant formula applications supporting HMO integration for immunity and development | 1.80% | High | Asia Pacific, Europe | High | Mid Term |
| Increasing clinical nutrition investments driving advanced prebiotic ingredient commercialization | 1.50% | Moderate | North America, Asia Pacific | Medium | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America held the largest regional share of the human milk oligosaccharides (HMO) market in 2025, bolstered by a well-established infant nutrition industry, strong commercialization capabilities, and early integration of advanced functional ingredients into premium formula products. The region’s leadership is strengthened by the presence of major manufacturers, mature regulatory and product development frameworks, and consistent demand for science-backed nutritional formulations. In practice, these conditions help accelerate ingredient adoption, shorten product launch cycles, and sustain higher penetration of HMO-enriched offerings across infant nutrition channels.
Asia Pacific is projected to expand at a 15.46% CAGR over the forecast period, with growth in the human milk oligosaccharides (HMO) market being impelled by rising uptake of fortified infant nutrition products and expanding demand for higher-value nutritional ingredients. The region’s momentum is shaped by increasing commercialization activity, broader access to modern retail and distribution networks, and stronger consumer interest in formulations that more closely replicate the functional profile of human milk. These adoption patterns are translating into faster market development as manufacturers scale product availability and target evolving nutrition preferences across diverse population centers.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants/Startups i Scale Low Medium High | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Science-Driven Ingredient DevelopmentGermany advances the human milk oligosaccharides market through strong expertise in nutritional science and specialized ingredient manufacturing. German producers emphasize clinically supported HMO development that aligns with evolving infant nutrition standards and product differentiation strategies.
France 🇫🇷
Clinical Nutrition ApplicationsFrance supports the human milk oligosaccharides market through continued emphasis on evidence-based nutritional ingredients. French companies explore HMO incorporation across infant nutrition portfolios while strengthening product development centered on scientifically validated health benefits.
Italy 🇮🇹
Specialized Nutrition ExpansionItaly is strengthening its human milk oligosaccharides market through growing interest in premium infant nutrition formulations. Italian manufacturers focus on incorporating advanced functional ingredients that enhance product value while meeting stringent quality and safety expectations.
Japan 🇯🇵
Premium Nutrition FormulationsJapan continues integrating human milk oligosaccharides into premium infant nutrition products that emphasize digestive and immune health. Japanese manufacturers prioritize high-quality ingredient production supported by advanced formulation capabilities and rigorous quality assurance practices.
South Korea 🇰🇷
Advanced Infant Formula FocusSouth Korea is expanding the use of human milk oligosaccharides as infant nutrition companies enhance premium product offerings. South Korean manufacturers invest in specialized formulation technologies that improve functional ingredient integration while addressing evolving consumer expectations.
United States 🇺🇸
Infant Nutrition InnovationThe U.S. human milk oligosaccharides market benefits from continuous innovation in infant nutrition and specialized nutritional ingredients. Companies in the U.S. focus on expanding HMO incorporation into premium infant formula while supporting research into broader nutritional applications.
Segment Leadership and Growth Trends
Human Milk Oligosaccharides (HMO) Market Share (%), Application, 2025
Go beyond the chart, access full insights & data tables
Request Free Sample ReportWithin the human milk oligosaccharides (HMO) market, Infant Formula held the dominant position in 2025 with an 86.17% share. This leadership is underpinned by the direct fit between HMOs and infant nutrition formulations, where manufacturers prioritize ingredients that closely align with the functional composition associated with human milk. Demand remains concentrated in this application because infant formula is the most established commercial use case for HMOs, with product development, formulation priorities, and purchasing patterns already centered on early-life nutrition.
Dietary Supplements are emerging as the fastest-growing application in the human milk oligosaccharides (HMO) market as HMO usage expands beyond infant-focused products into broader wellness-oriented formulations. Growth in this segment is being backed by rising interest in gut health and microbiome-support ingredients, which makes dietary supplements a practical route for HMO adoption relative to more established applications. Compared with infant formula, the supplement category offers a wider platform for product innovation and consumer targeting, helping it gain momentum at a faster pace.
Type Segment Analysis: 2'FL (Largest Segment) vs DFL (Fastest-Growing Segment)
By type, 2'FL accounted for the largest position in the human milk oligosaccharides (HMO) market in 2025, capturing a 47.28% share. Its leading role reflects the fact that 2'FL is the most established HMO type in commercial product development, particularly in infant nutrition where ingredient familiarity and formulation consistency matter. The segment’s scale is backed by stronger incorporation into existing HMO product portfolios, allowing 2'FL to maintain broad market presence as manufacturers continue to rely on proven ingredient formats.
DFL is the fastest-growing type in the human milk oligosaccharides (HMO) market as producers and formulators broaden their focus beyond core HMO offerings toward more diverse compositions. Its momentum is tied to the market’s shift toward expanded ingredient differentiation, where companies seek to develop products with more targeted or advanced HMO blends. Relative to 2'FL, DFL benefits from this next wave of formulation expansion, which is helping it grow faster as the market moves toward a broader range of HMO types.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Application | Food & Beverages, Dietary Supplements, Infant Formula, Pharmaceuticals | Infant Formula | Dietary Supplements |
| Type | 2'FL, 3'FL, 3'SL, 6'SL, LNT, LNnT, DFL | 2'FL | DFL |
Competitive Landscape and Market Positioning
1. DSM-Firmenich AG (Switzerland)
2. BASF SE (Germany)
3. Chr. Hansen Holding A/S (Denmark)
4. FrieslandCampina Ingredients (Netherlands)
5. Glycom A/S (Denmark)
6. Inbiose NV (Belgium)
7. Kyowa Hakko Bio Co. Ltd. (Japan)
8. zuChem Inc. (United States)
9. Biosynth AG (Switzerland)
10. Dextra Laboratories Limited (United Kingdom)
The human milk oligosaccharides (HMO) market is expanding with advanced bioengineering techniques that improve infant nutrition formulations. Enhanced synthesis methods are supporting more scalable production of functional ingredients. The human milk oligosaccharides (HMO) market is also driven by increasing demand for premium infant health solutions.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| No companies available. | |||||||
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| dsm-firmenich | Mar-26 | dsm-firmenich secured regulatory approvals for a suite of HMO ingredients, including 3’-SL, 2’-FL/DFL, LNT, and 6’-SL, across China, Malaysia, and Thailand. This significant geographic expansion of its product portfolio establishes the company as a first-mover in the region, materially enhancing its competitive position and ability to supply the growing early-life nutrition market in Asia. |
| BENEO and WACKER | May-25 | BENEO and WACKER executed the global commercial launch of 2’-Fucosyllactose (2’-FL), a key HMO ingredient, following their strategic partnership. This initiative is designed to scale the global supply of high-quality HMOs, providing both large-scale and specialized infant formula manufacturers with consistent access to this critical, widely-studied nutritional component. |
| A2 Milk Company | Nov-25 | A2 Milk Company deepened its strategic partnership with China State Farm to include English-label infant formula within Chinese cross-border e-commerce channels. This expansion of distribution infrastructure strengthens the company’s market access and operational footprint in China, a primary growth region for the global infant nutrition and dairy sector. |
| Friso | Oct-25 | Friso introduced Friso Pro, a premium, fully-imported infant formula manufactured in the Netherlands. The launch represents a strategic portfolio expansion, utilizing advanced formulations designed to improve digestive and immune health outcomes, directly targeting the high-end segment of the international infant nutrition market. |
| Yili | May-25 | Yili launched its Pro-Kido infant formula in China as a component of its international growth strategy. This product rollout reinforces Yili’s competitive positioning in the specialized infant nutrition segment and facilitates the firm’s broader objective of scaling its dairy business through advanced, value-added nutritional offerings in key international markets. |
Explore This Report
Click a section of the wheel — or its numbered marker — to preview the custom segmentation, custom table of contents, or related reports available for this market.
Human Milk Oligosaccharides (HMO) Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| No segment data available. | |
Human Milk Oligosaccharides (HMO) Market — report.custom
| Custom Chapter | Custom Details | ||
|---|---|---|---|
| No custom TOC data available. | |||
Need a different cut of the data?
Request Custom ResearchWhat is the market valuation of human milk oligosaccharides?
What is the forecasted size of the human milk oligosaccharides industry?
How is rising consumer focus on gut health expanding the use of HMOs beyond infant nutrition into broader wellness applications?
What is driving the strategic integration of HMOs into infant formula development and clinical nutrition pipelines?
Why does Infant Formula lead the human milk oligosaccharides (HMO) market by application?
Why are Dietary Supplements the fastest-growing application in the human milk oligosaccharides (HMO) market?
Why does North America lead the human milk oligosaccharides (HMO) market?
How is Asia Pacific driving growth in the HMO market?
Which companies dominate the human milk oligosaccharides landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Food & Beverage Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source Category | Research Sources | Purpose |
|---|---|---|
| Government Publications | Government agencies, statistical departments, regulatory bodies | Industry statistics, regulatory insights, and policy analysis |
| Company Disclosures | Annual reports, investor presentations, financial filings | Company performance, business strategy, and market positioning |
| Trade Associations | Industry associations and professional organizations | Industry developments, standards, and market perspectives |
| Technical Literature | Research papers, technical publications, academic journals | Technology developments and technical validation |
| Patent Analysis | Patent databases and intellectual property publications | Innovation trends, technology activity, and competitive research |
| Industry Databases | Established research databases and market intelligence resources | Market benchmarking, historical data, and industry analysis |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization